Viewpoint

The following are views expressed from a number of key practioners in the field of metabolomics

A Pharma Perspective on Metabolomics: Opportunities & Realities

          John Haselden, Director of Metabolomics, GSK

FDA’s Critical Path Initiative: Opportunities for Metabolomics

          Richard Beger, Center for Metabolomics, NCTR